KalVista Pharmaceuticals (KALV) Cash from Financing Activities (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 10 years of Cash from Financing Activities data on file, last reported at $23.2 million in Q3 2025.

• For the quarter ending Q3 2025, Cash from Financing Activities rose 673.67% year-over-year to $23.2 million; the trailing twelve-month figure through Jul 2025 stood at $31.2 million (down 79.7% YoY), and the FY2025 full-year result was $159.7 million, up 5.98% from the prior year.
• Cash from Financing Activities improved to $23.2 million in Q3 2025, from $4.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $210.3 million in Q2 2021 to a low of -$33000.0 in Q2 2023.
• A 5-year average of $25.2 million and a median of $451500.0 in 2021 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 21030700.0% in 2021 and sank 123.91% in 2023, its largest moves.
• Tracing KALV's Cash from Financing Activities over 5 years: stood at $63000.0 in 2021, then surged by 166.67% to $168000.0 in 2022, then retreated by 23.81% to $128000.0 in 2023, then surged by 130.47% to $295000.0 in 2024, then soared by 7767.8% to $23.2 million in 2025.
• Business Quant data shows KALV's Cash from Financing Activities at $23.2 million in Q3 2025, $4.7 million in Q2 2025, and $295000.0 in Q4 2024.